SHORT COMMUNICATION

# Accumulation of IL-17<sup>+</sup> V $\gamma$ 6<sup>+</sup> $\gamma\delta$ T cells in pregnant mice is not associated with spontaneous abortion

Barbara Polese<sup>1</sup> (p), Virginie Gridelet<sup>1</sup>, Sophie Perrier d'Hauterive<sup>1</sup>, Chantal Renard<sup>1</sup>, Carine Munaut<sup>2</sup>, Henri Martens<sup>1</sup>, David Vermijlen<sup>3</sup>, Irah L King<sup>4</sup>, Nathalie Jacobs<sup>5</sup> & Vincent Geenen<sup>1</sup>

<sup>1</sup>GIGA-I<sup>3</sup> Center of Immunoendocrinology, GIGA Research Institute, University of Liege, Liege, Belgium

<sup>2</sup>GIGA Laboratory of Tumor and Development Biology (LBTD), GIGA Research Institute, University of Liege, Liege, Belgium <sup>3</sup>Department of Pharmacotherapy and Pharmaceutics and Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Bruxelles, Belgium

<sup>4</sup>Department of Microbiology and Immunology, Microbiome and Disease Tolerance Centre, McGill University, Montreal, QC, Canada <sup>5</sup>GIGA-I<sup>3</sup> Laboratory of Cellular and Molecular Immunology, GIGA Research Institute, University of Liege, Liege, Belgium

#### Correspondence

B Polese, PhD, GIGA-I<sup>3</sup> Center of Immunoendocrinology CHU-B34, GIGA Research Institute, University of Liege, Liege B-4000, Belgium. E-mail: bpolese@uliege.be

Received 17 August 2017; Revised 4 and 21 December 2017; Accepted 22 December 2017

doi: 10.1002/cti2.1008

Clinical & Translational Immunology 2018; 7: e1008

#### Abstract

Introduction. Pregnancy is an immune paradox. While the immune system is required for embryo implantation, placental development and progression of gestation, excessive inflammation is associated with pregnancy failure. Similarly, the cytokine IL-17A plays an important role in defence against extracellular pathogens, but its dysregulation can lead to pathogenic inflammation and tissue damage. Although expression of IL-17 has been reported during pregnancy, the cellular source of this cytokine and its relevance to gestation are not clear. Objectives. Here we define the kinetics and cellular source of IL-17A in the uterus during healthy and abortion-prone murine pregnancy. Methods. The CBA/J x DBA/2J abortion-prone mating was used and compared to CBA/J x BALB/c control mating. Results. We demonstrate that, irrespective of gestational health, the number of IL-17-producing cells peaks during midterm pregnancy and is largely derived from the  $\gamma\delta$  T-cell lineage. We identify  $\gamma\delta$  T, Th17, CD8 T and NKT cells as the cellular source of IL-17A in pregnant mice. Furthermore, we positively identify the  $V\gamma 6^+$  subset of uterine  $\gamma\delta$  T cells as the main producer of IL-17A during both healthy pregnancy and abortive pregnancy. Conclusions. To conclude, the accumulation of uterine IL-17<sup>+</sup> innate-like T cells appears not to adversely impact the developing foetus. Collectively, our results show that IL-17<sup>+</sup>  $\gamma\delta$  T cells are present in the uterus throughout the course of normal gestation and therefore may play an important role in healthy pregnancy.

**Keywords:** abortion, gamma delta T cells, interleukin-17, pregnancy.

# **INTRODUCTION**

During normal pregnancy, the maternal host coopts cells of the innate and adaptive immune system to accept the semi-allograft foetus while remaining vigilant against pathogen invasion.<sup>1</sup> Thus, pregnancy requires a tightly regulated balance between immune regulation and surveillance. Indeed, lack of immune control in the uterus can lead to excessive inflammation and pregnancy failure.<sup>2</sup>

Interleukin-17A (IL-17A) is an inflammatory cytokine that plays an important role in defence against extracellular pathogens at barrier sites such as the female reproductive tract but is also involved in various autoimmune reactions and graft rejection<sup>3</sup> via sustained neutrophil recruitment and chronic inflammation.<sup>4</sup> However, the contribution of IL-17 to uterine health and the developing foetus is unclear. Early studies suggested that IL-17 was associated with complications during pregnancy and infertility.<sup>5–7</sup> However, more recent studies suggest a beneficial function for IL-17 during pregnancy including the promotion of implantation.<sup>8–10</sup> embryo Importantly, new biologics targeting IL-17A and its receptor have shown clinical efficacy in the treatment of psoriatic disease and rheumatoid arthritis.<sup>3</sup> Given the prevalence of these diseases in the female population and the requirement for lifelong use of these medications to prevent disease progression, understanding the impact of this cytokine pathway on pregnancy is vital for reproductive health.

Although first identified as a CD4<sup>+</sup> T cellderived cytokine, recent studies examining nonlymphoid barrier tissues such as the lung, skin and gut indicate  $\gamma\delta$  T cells are a potent source of IL-17A.<sup>11–13</sup>  $\gamma\delta$  T cells are thymus-derived and express a TCR (T-cell receptor) composed of  $\gamma$  and  $\delta$  subunits and exhibit less variability than classical  $\alpha\beta$  T cells.<sup>14</sup>  $\gamma\delta$  T cells also display innate-like properties whereby exposure to inflammatory cytokines is sufficient to induce robust cytokine secretion in the absence of specific antigen recognition. Although a previous study described the expansion of uterine IL-17A-producing  $\gamma\delta$  T cells during pregnancy, the kinetics of this response and whether this population is the dominant source of this cytokine during pregnancy was not examined.<sup>15</sup> By comparing healthy pregnancy and abortion-prone murine pregnancy, here we determine the kinetics of IL-17A production in the uterus and identify  $V\gamma 6^+ \gamma \delta$ T cells as the dominant source of this cytokine, regardless of the health of the developing foetus.

# **RESULTS AND DISCUSSION**

# Regulatory and IL-17<sup>+</sup> T cells are increased throughout normal and abortive gestation

In order to study IL-17A-producing cells in normal conditions as well as in abortive gestation, we established a mouse model of abortion-prone pregnancy. In this model, CBA/J x DBA/2J mating (called 'abortive mating') results in an increased frequency of rejected foetuses than CBA/J x BALB/c control breeders (called 'control mating').<sup>16</sup> This model was tested in our animal care facility and, as expected, implantation rates were not significantly different between groups, while a significantly higher resorption rate was observed in CBA/J x DBA/2J mating (Figure 1a, b). Implantation and abortion rates were similar for all groups of this

**Figure 1.** Regulatory and IL-17<sup>+</sup> T cells are increased throughout normal and abortive gestation. (a) Number of implanted foetuses counted at day 12.5 of pregnancy in uteri from DBA/2J- or BALB/c-mated CBA/J females, n = 16 per group. (b) Rate of foetal resorption calculated at day 12.5 of pregnancy in uteri from DBA/2J- or BALB/c-mated CBA/J females, n = 16 per group. (c) RT-qPCR analysis of Foxp3 mRNA expression in uterine tissue of pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5, n = 6-12. (d) RT-qPCR analysis of I10 mRNA expression in uterine tissue of pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5, n = 6-12. (e) Percentage of Treg (CD4<sup>+</sup> Foxp3<sup>+</sup> cells) amongst CD3<sup>+</sup> CD4<sup>+</sup> cells in uteri from pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5 and from nonpregnant BALB/c females, n = 6-12 per group. (f) Absolute Treg cell numbers in uteri from pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5 and from pregnant 1.5, 4.5, 6.5, 12.5 and from pregnancy 1.5, 4.5, 6.5, 12.5 and from nonpregnant 1.5, 4.5, 6.5, 12.5 and from nonpregnant BALB/c females at oestrus phase, n = 6-12 per group. (h) Absolute cell numbers of IL-17A-producing T cells (CD3<sup>+</sup> IL-17A<sup>+</sup> cells amongst CD45<sup>+</sup> cells) in uteri from pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5 and from nonpregnant BALB/c females at oestrus phase, n = 6-12 per group. (h) Absolute cell numbers of IL-17A-producing T cells (CD3<sup>+</sup> IL-17A<sup>+</sup> cells amongst CD45<sup>+</sup> cells) in uteri from pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5 and from nonpregnant BALB/c females, n = 5-12 per group. (i) Correlation between the foetal resorption rate and IL-17A-producing Clas<sup>+</sup> IL-17A<sup>+</sup> cells amongst CD45<sup>+</sup> cells) in uteri from pregnant DBA/2J- or BALB/c-mated CBA/J females on days of pregnancy 1.5, 4.5, 6.5, 12.5 and from



© 2018 The Authors. *Clinical & Translational Immunology* published by John Wiley & Sons Australia, Ltd on behalf of Australasian Society for Immunology Inc.

study. To further validate our model, we assessed the kinetics of Foxp3<sup>+</sup> T regulatory (Treg) cell accumulation, an immunoregulatory lymphocyte subset that plays a critical role at the maternalfoetal interface.<sup>5</sup> In order to maximise cell yield and to provide a general overview of the entire uterine immune cell compartment during pregnancy, we used entire uterine tissue. Consistent with previous studies,<sup>17,18</sup> Treg-associated genes Foxp3 and II10 expression was significantly increased during the implantation period, corresponding to day 4.5 (Figure 1c, d). In addition, the proportion as well as absolute cell number of Treg cells were significantly increased in the uterus throughout pregnancy and particularly at the implantation period and midgestation (day 12.5) (Figure 1e, f). However, there were no significant differences between healthy and abortive matings. This result is discordant with a study showing decreased Treg proportion in abortive mating using a different gating strategy<sup>19</sup> but in accordance with another paper using the same gating strategy as in our studies.<sup>20</sup> Since Treg have been shown to be particularly important for implantation rather than midgestation,<sup>18</sup> and our model does not exhibit defective implantation, it is conceivable that Treq are not key players at this latter stage of pregnancy.

We next determined the kinetics of IL-17Aproducing cells during the course of gestation. While no significant variation was found in the proportion of uterine IL-17<sup>+</sup> leucocytes (likely due to a recruitment of other cell types), the absolute number increased at implantation as well as during midgestation compared to nonpregnant controls, the latter time point corresponding to the time of visible embryo rejection. The increase during the embryo resorption period suggested that IL-17<sup>+</sup> cells could be linked with abortion.

However, we found no significant correlation between the proportion or number of IL-17Aproducing cells and abortion rates (Figure 1g-i). Similarly, the analysis of decidua samples of viable and resorbed foetus revealed no difference for IL-17A-producing cells (data not shown). These data suggest that IL-17A is not a key mediator of abortion in this model, an unexpected result given the prominent concept that IL-17-producing cells are thought to be detrimental for pregnancy. Indeed, Th17 cells are increased in infertile women,<sup>5</sup> and IL-17A injection can lead to in the abortion-prone model.<sup>7,21</sup> abortion However, increasing evidence suggests that Th17 cells may not necessarily be deleterious for gestation. For example, decidual Th17 cells are nonpathogenic and could be beneficial when they also produce IL-4.9 Moreover, IL-17A can promote trophoblast invasion and proliferation as well as progesterone secretion, which are essential for gestation.8,22

# $\gamma\delta$ T cells are the main producers of IL-17A in pregnant mice

We next sought to determine the cellular source of IL-17A in pregnant mice (Figure 2a). As the peak of the IL-17 response was at day 12.5 of gestation, we examined the phenotype of IL-17<sup>+</sup> cells at that time point (Figure 1f). Consistent with previous studies examining IL-17A during pregnancy, a small population of IL-17-producing CD4<sup>+</sup>  $\alpha\beta$  T (Th17) cells was detected (Figure 2a).<sup>5</sup> Unexpectedly, however, the majority of IL-17<sup>+</sup> T cells were  $\gamma\delta$  TCR<sup>+</sup> (Figure 2a). Nevertheless, the frequency of IL-17<sup>+</sup>  $\gamma\delta$  T cells did not differ between healthy and abortion-prone females (Figure 2b). In addition, a small population of

**Figure 2.**  $\gamma\delta$  T cells are the main producers of IL-17A in pregnant mice. (a) Frequency of IL-17A-producing cells in the uterus of a representative pregnant BALB/c-mated CBA/J female at day 12.5 of pregnancy. Numbers indicate frequency of the gated population. On the left, corresponding positive staining controls from CD45<sup>+</sup> IL-17A cells. On the right, IL-17A<sup>+</sup> cells.  $\gamma\delta$  TCR<sup>+</sup> CD3<sup>+</sup> were used for  $\gamma\delta$  T cells. CD4 and CD8 were used in addition to CD3 cells to identify CD4 and CD8 T cells. CD49b and CD122 were used to identify NK cells, in addition to CD3 for NKT cells. (b) Percentage of IL-17<sup>+</sup> cells amongst  $\gamma\delta$  T cells in uteri of pregnant DBA/2J- or BALB/c-mated CBA/J females on days 12.5 of pregnancy and of nonpregnant CBA/J females on day of 12.5 of pregnancy, n = 5-8 per group. (c) Percentage of  $\gamma\delta$  T cells in various organs of pregnant DBA/2J- or BALB/c-mated CBA/J females on day of 12.5 of pregnancy, n = 5-8 per group. (d) Percentage of IL-17A<sup>+</sup> cells) in various organs of pregnant DBA/2J- or BALB/c-mated CBA/J females on day of 12.5 of pregnancy, n = 5-8 per group. (e) Frequency of cytokine-producing- $\gamma\delta$  T cells (cytokine+ amongst CD3<sup>+</sup>  $\gamma\delta$ TCR<sup>+</sup> cells) in stimulated (with PMA and ionomycin) total uterine single cells of a representative pregnant BALB/c-mated CBA/J females at day 12.5 of pregnancy. (f) Percentage of cytokine-producing  $\gamma\delta$  T cells (IL-10<sup>+</sup>, IL-17<sup>+</sup> and IFN $\gamma^+$  cells amongst CD3<sup>+</sup>  $\gamma\delta$ TCR<sup>+</sup> cells) in uteri of pregnancy. (f) Percentage of cytokine-producing  $\gamma\delta$  T cells (IL-10<sup>+</sup>, IL-17<sup>+</sup> and IFN $\gamma^+$  cells amongst CD3<sup>+</sup>  $\gamma\delta$ TCR<sup>+</sup> cells) in uteri of pregnant DBA/2J- or BALB/c-mated CBA/J females on days 4.5 and 12.5 of pregnancy and of nonpregnant CBA/J females, n = 3-10 per group. Results are shown as mean  $\pm$  SEM and are representative of at least three experiments. Mann–Whitney test was used. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.  $\blacktriangle$  Nonpregnant, O CBA/J x BALB/c, CBA/J x DBA/2J.



© 2018 The Authors. *Clinical & Translational Immunology* published by John Wiley & Sons Australia, Ltd on behalf of Australasian Society for Immunology Inc.

CD3<sup>-</sup>IL-17A<sup>+</sup> cells was observed (likely type 3 innate lymphoid cells, not depicted).<sup>23</sup>

The proportion of  $\gamma\delta$  T cells was remarkably higher in the uterus when compared to other lymphoid organs (Figure 2c). In addition, we noticed that  $\gamma\delta$  T cells were the main producers of IL-17A in the uterus as well as the uterusdraining inguinal lymph nodes at midgestation, yet were not different between groups of pregnant females (Figure 2d). As some reports indicated that  $\gamma\delta$  T cells may be protective during pregnancy,<sup>24,25</sup> we examined whether this cell subset also produced IL-10 and IFN $\gamma$ , cytokines associated with gestational two health.<sup>26,27</sup> However, few  $\gamma\delta$  T cells were positive for IL-10 or IFN $\gamma$  production in either group (Figure 2e, f).

# V $\gamma$ 6<sup>+</sup> T cells are the main subpopulation of $\gamma\delta$ T cells and dominant producer of IL-17A in pregnant mice

Previous work has suggested that uterine  $\gamma\delta$  T cells have limited TCR diversity and predominantly express the Vγ6 subunit. However, these conclusions were only based on transcriptional studies<sup>28</sup> or by exclusion of other surface V $\gamma$ subunit expression.<sup>15</sup> To positively determine the dominant subset of  $\gamma\delta$  T cells in the uterus during pregnancy, we used gPCR and flow cytometrybased assays. Consistent with previous gene expression studies,<sup>28</sup> RT-qPCR analysis revealed an enrichment for Vy6 mRNA. Furthermore, the predominance of this V $\gamma$  subunit remained stable throughout pregnancy (Figure 3a). To determine whether this pattern of  $V\gamma$  expression translated to surface protein expression, we performed flow cytometry using antibodies specific for V $\gamma$ 1, V $\gamma$ 4 and V $\gamma$ 6 TCR subunits. Uterine  $\gamma\delta$  T cells expressed higher levels of CD3 compared to those isolated from lymph nodes and, consistent with our transcriptional analyses,  $V\gamma6^+$  cells were the dominant subtype of  $\gamma\delta$  T cells found in pregnant mice (Figure 3b, c). Notably, the percentage of uterine  $V\gamma6^+$  T cells at midgestation was not different between healthy and abortion-prone dames (Figure 3d).

Although a recent study by Pinget *et al.* suggested that  $V\gamma6^+$  T cells were an important source of IL-17A, they used high expression of CD3 (i.e. CD3<sup>++</sup>) as a proxy for  $V\gamma6$  expression but did not positively identify these cells.<sup>15,29</sup> To confirm that uterine  $V\gamma6^+$  T cells were the dominant source of IL-17A, we combined  $V\gamma$  subunit staining with intracellular cytokine staining. Indeed, the percentage of IL-17A<sup>+</sup>  $V\gamma6^+$  cells was significantly greater than  $V\gamma4^+$  or  $V\gamma1^+$  T cells (Figure 3d). Again, however, the percentage of IL-17A<sup>+</sup>  $V\gamma6^+$  T cells was similar irrespective of gestational health (Figure 3e).

Regulation of IL-17A production at barrier sites is critical for immune homoeostasis and health. Our study is the first to report the kinetics of IL-17A<sup>+</sup> T cells in the uterus over the course of both normal pregnancy and abortion-prone murine pregnancy. In addition, we have definitively determined that  $V\gamma 6^+$  T cells are the dominant source of IL-17A in pregnant mice. The frequency of total IL-17<sup>+</sup> cells, IL-17<sup>+</sup>  $\gamma\delta$  T and IL-17A<sup>+</sup> V $\gamma$ 6<sup>+</sup> T cells did not differ between healthy and abortion-prone females. These data show that IL-17A is not a key mediator of abortion in this model. As the source and number of uterine IL-17<sup>+</sup>  $\gamma\delta$  T cells occur independent of gestational health, our data suggest an alternative role for IL-17 production during pregnancy that may have evolved to combat pathogenic challenge during the course of gestation rather than directly affecting foetal health. Given the recent development of therapies that target the IL-17 pathway, it will be important to further investigate

**Figure 3.**  $V\gamma6^+$  T cells are the main subpopulation of  $\gamma\delta$  T cells and dominant producer of IL-17A in pregnant mice. **(a)** RT-qPCR analysis of TCR $\gamma$  subunit expression in uterine tissue from nonpregnant CBA/J females and pregnant DBA/2J- or BALB/c-mated CBA/J females on days 4.5 or 12.5 of pregnancy, n = 5-6 per group. **(b)** CD3 expression on  $\gamma\delta$  T cells from uterus and lymph nodes at day 12.5 of gestation. On the left, histogram showing a modal distribution of CD3 expression by uterine and lymph nodes total  $\gamma\delta$  T cells. On the right, CD3 MFI by uterine and lymph nodes total  $\gamma\delta$  T cells. **(c)** Frequency of  $\gamma\delta$  T subtypes in unstimulated  $\gamma\delta$  T cells and frequency of IL-17A<sup>+</sup>-producing-stimulated (with PMA and ionomycin) V $\gamma6$   $\gamma\delta$  T cells, from the total uterine single cells suspension of a representative pregnant BALB/c-mated CBA/J female at day 12.5 of pregnancy. Numbers indicate frequency of gated population. **(d)** Percentage of  $\gamma\delta$  T subtypes (V $\gamma^+$  cells amongst CD3<sup>+</sup>  $\gamma\delta$ TCR<sup>+</sup> cells) in uterus of pregnant DBA/2J- or BALB/c-mated CBA/J females on day 12.5 of pregnancy and of nonpregnant CBA/J females, n = 3-6 per group. **(e)** Percentage of IL-17A-producing  $\gamma\delta$  T subtypes (IL-17A<sup>+</sup> cells amongst CD3<sup>+</sup>  $\gamma\delta$ TCR<sup>+</sup>V $\gamma^+$  cells) in the uteri of pregnant DBA/2J- or BALB/c-mated CBA/J females on day 12.5 of pregnancy and of nonpregnant CBA/J females, n = 3-6 per group. **(e)** Percentage of IL-17A-producing  $\gamma\delta$  T subtypes (IL-17A<sup>+</sup> cells amongst CD3<sup>+</sup>  $\gamma\delta$ TCR<sup>+</sup>V $\gamma^+$  cells) in the uteri of pregnant DBA/2J- or BALB/c-mated CBA/J females on day 12.5 of pregnancy. Results are shown as mean  $\pm$  SEM and are representative of at least three experiments. Mann–Whitney test was used. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.01 **(b)** Nonpregnant, O CBA/J x BALB/c, **(CBA/J x DBA/2J**.



© 2018 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australasian Society for Immunology Inc.

how modulating the function of this cytokine may impact the uterine microenvironment and the complex immunoregulatory pathways operating during human pregnancy.

# **METHODS**

#### Mice

CBA/J female, BALB/c and DBA/2J male mice were obtained from Charles River (France) and housed in SPF (specific pathogen free) conditions and used at 8-12 weeks of age. Mating was performed in trios, and the presence of a vaginal plug was assessed every morning and its appearance was considered as day 0.5. Pregnant females were then separated from the male and sacrificed at days 1.5, 4.5, 6.5 or 12.5 of pregnancy. At day 12.5, normal and naturally aborted foetuses were counted for every group of mice. Inquinal lymph nodes, thymi and spleens were collected before cell isolation. Entire uteri were also taken and placenta and its associated membranes were carefully removed before uteri were opened longitudinally for cell isolation. All experiments were approved by the Animal Ethics Committee of the University of Liege (permit N° 1373).

#### **Flow cytometry**

Single-cell suspensions were prepared by mechanical (lymph nodes, thymi and spleens tissues were crushed with a 5-ml syringe plunger (VWR, USA)) or enzymatic disruption (uterine tissues were digested during 2 h at 37°C with 1 mg  $mI^{-1}$  collagenase A and 10  $\mu g$   $mI^{-1}$  DNAse I solution in RPMI medium). Cells dedicated to measurement of cytokine production by flow cytometry were first stimulated with 100 ng ml<sup>-1</sup> PMA (phorbol myristate acetate) and 1  $\mu$ g ml<sup>-1</sup> ionomycin (Sigma, USA) for 3 h at 37°C with 5% CO2. For analysis of Treg cells, the following antibodies (Ab) were used as follows: anti-mouse CD45.2 (104), CD3e (145-2C11), CD4 (RM4-5), purchased from BD Biosciences (Becton Dickinson, USA) and anti-mouse Foxp3 (FJK-16s) from eBiosciences (Affymetrix, USA). Transcription factor buffer set from BD Pharmingen (Becton Dickinson, USA) was used with manufacturer's protocol. For the study of cytokineproducing cells and  $\gamma\delta$  T cells, the following antibodies (Ab) were used as follows: anti-mouse CD45.2 (104), CD45 (30-F11), CD3e (500A2), CD8 (53-6.7), IL-10 (JES5-16E3) and IFN-γ (XMG1.2) from BD Biosciences and  $\gamma\delta$  TCR (eBioGL3), CD122 (TM-b1), TCR Vy2 (UC3-10A6), IL-17A (eBio17B7) and antirat IgM (RM-7B4) from eBiosciences (Affymetrix, USA), antimouse TCR Vy1.1/Cr4 (2.11) from Biolegend (USA). Antimouse IgM Vy6 antibody (clone 17D1) was produced and kindly provided by Immo Prinz (Institute of Immunology, Hannover Medical School, Hannover, Germany). The BD Cytofix/Cytoperm Fixation/Permeabilization kit from BD Biosciences was used for intracellular cytokine staining according manufacturer's instructions. to FACS (fluorescence-activated cell sorting) Verse machine with FACS Suite software (BD Biosciences) were used for flow cytometry. FCS files were analysed using Flow Jo V10 software. Gating strategy for T analysis was adapted from Rei  $et \ al.^{30}$ 

#### **RNA extraction**

Lymph nodes and thymic (as control) and uterine tissue samples were removed and kept in RNA Later (Qiagen, Germany) before RNA extraction. Tissues were disrupted with MagNA Lyser Green Beads (Roche, Germany) in a MagNA Lyser instrument (Roche, Germany), and total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, USA) according to manufacturer's instructions.

#### **RT-qPCR**

For RT-qPCR, the Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany) and the Takyon No Rox SYBR MasterMix (Eurogentec, Belgium) were used with prevalidated specific primers purchased from Eurogentec (Belgium). RT-qPCR products were sequenced at the Sequencing platform of the GIGA Genomics Facility by Sanger method to ensure correct sequence amplification. Relative gene expression was determined using the  $2^{-}\Delta\Delta$ Ct method. Hypoxanthineguanine phosphoribosyltransferase, succinate dehydrogenase complex flavoprotein subunit A and  $\beta$ -actin were used as housekeeping genes, and nonpregnant mice were used as untreated controls.

#### **Statistical analysis**

Statistical analyses were performed with Prism 4.0 software (GraphPad). Normal distribution was first determined with Shapiro–Wilk normality test. When data were normally distributed, unpaired *t* Student tests were used. Mann–Whitney test was applied when normality was not observed. Parametric one-way analysis of variance (ANOVA) or nonparametric Kruskal–Wallis tests were used to evaluate the data variance throughout pregnancy. Mean differences were considered significant when P < 0.05. All results are shown as mean  $\pm$  SEM.

### ACKNOWLEDGMENTS

The authors thank Prof. Immo Prinz (Institute of Immunology, Hannover Medical School, Hannover, Germany) for providing the anti-mouse-V $\gamma$ 6 antibody, the GIGA Animal Facility for animal management and the Cell Imaging and Flow Cytometry GIGA Technological Platform for their help for flow cytometry experiments design and analyses. This work was supported by grants from the 'Fonds National de la Recherche Scientifique' (F.R.S-FNRS; Belgium) and the 'Fonds Léon Fredericq' (Belgium).

## **CONFLICT OF INTEREST**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### REFERENCES

- 1. Medawar P. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. *Symp Soc Exp Biol* 1953; **7**: 320–338.
- 2. Challis JR, Lockwood CJ, Myatt L et al. Inflammation and pregnancy. *Reprod Sci* 2009; **16**: 206–215.
- 3. Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. *Nat Immunol* 2017; **18**: 612–621.
- 4. Korn T, Bettelli E, Oukka M et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485–517.
- 5. Saito S, Nakashima A, Shima T *et al.* Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. *Am J Reprod Immunol* 2010; **63**: 601–610.
- 6. Liu YS, Wu L, Tong XH *et al.* Study on the relationship between Th17 cells and unexplained recurrent spontaneous abortion. *Am J Reprod Immunol* 2011; **65**: 503–511.
- Xu WM, Xiao ZN, Wang XB et al. IL-17 induces fetal loss in a CBA/JxBALB/c mouse model, and an anti-IL-17 antibody prevents fetal loss in a CBA/JxDBA/2 mouse model. Am J Reprod Immunol 2016; 75: 51–58.
- 8. Wu HX, Jin LP, Xu B et al. Decidual stromal cells recruit Th17 cells into decidua to promote proliferation and invasion of human trophoblast cells by secreting IL-17. *Cell Mol Immunol* 2014; **11**: 253–262.
- Lombardelli L, Logiodice F, Aguerre-Girr M et al. Interleukin-17-producing decidual CD4<sup>+</sup> T cells are not deleterious for human pregnancy when they also produce interleukin-4. *Clin Mol Allergy* 2016; 14: 1.
- 10. Song ZH, Li ZY, Li DD *et al.* Seminal plasma induces inflammation in the uterus through the gammadelta T/ IL-17 pathway. *Sci Rep* 2016; **6**: 25118.
- Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17<sup>+</sup> T helper cells. Cell 2006; **126**: 1121–1133.
- Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate lymphoid cells. *Eur J Immunol* 2012; 42: 2221–2231.
- Papotto PH, Ribot JC, Silva-Santos B. IL-17<sup>+</sup> gammadelta T cells as kick-starters of inflammation. *Nat Immunol* 2017; 18: 604–611.
- 14. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. *Nat Rev Immunol* 2013; **13**: 88–100.
- Pinget GV, Corpuz TM, Stolp J et al. The majority of murine gammadelta T cells at the maternal-fetal interface in pregnancy produce IL-17. *Immunol Cell Biol* 2016; 94: 623–630.
- 16. Chaouat G, Clark DA, Wegmann TG. Genetic aspects of the CBA  $\times$  DBA/2 and B10  $\times$  B10.A models of murine pregnancy failure and its prevention by lymphocyte immunisation. *Early Pregnancy Loss* 1988: 89–102.
- Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. *Nat Immunol* 2004; 5: 266–271.

- Shima T, Sasaki Y, Itoh M et al. Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice. J Reprod Immunol 2010; 85: 121–129.
- Zenclussen AC, Gerlof K, Zenclussen ML et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancyinduced CD4<sup>+</sup> CD25<sup>+</sup> T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005; 166: 811–822.
- 20. Thuere C, Zenclussen ML, Schumacher A et al. Kinetics of regulatory T cells during murine pregnancy. Am J Reprod Immunol 2007; **58**: 514–523.
- Wang WJ, Liu FJ, Xin L et al. Adoptive transfer of pregnancy-induced CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells reverses the increase in abortion rate caused by interleukin 17 in the CBA/JxBALB/c mouse model. *Hum Reprod* 2014; 29: 946–952.
- 22. Pongcharoen S, Supalap K. Interleukin-17 increased progesterone secretion by JEG-3 human choriocarcinoma cells. *Am J Reprod Immunol* 2009; **61**: 261–264.
- 23. Vacca P, Montaldo E, Croxatto D *et al.* Identification of diverse innate lymphoid cells in human decidua. *Mucosal Immunol* 2015; **8**: 254–264.
- Nagaeva O, Jonsson L, Mincheva-Nilsson L. Dominant IL-10 and TGF-beta mRNA expression in gammadeltaT cells of human early pregnancy decidua suggests immunoregulatory potential. *Am J Reprod Immunol* 2002; 48: 9–17.
- 25. Fan DX, Duan J, Li MQ *et al.* The decidual gamma-delta T cells up-regulate the biological functions of trophoblasts via IL-10 secretion in early human pregnancy. *Clin Immunol* 2011; **141**: 284–292.
- 26. Thaxton JE, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. *Am J Reprod Immunol* 2010; **63**: 482–491.
- Murphy SP, Tayade C, Ashkar AA et al. Interferon gamma in successful pregnancies. Biol Reprod 2009; 80: 848–859.
- Itohara S, Farr AG, Lafaille JJ *et al.* Homing of a gamma delta thymocyte subset with homogeneous T-cell receptors to mucosal epithelia. *Nature* 1990; 343: 754– 757.
- 29. Paget C, Chow MT, Gherardin NA *et al.* CD3bright signals on gammadelta T cells identify IL-17A-producing Vgamma6Vdelta1 + T cells. *Immunol Cell Biol* 2015; **93**: 198–212.
- Rei M, Goncalves-Sousa N, Lanca T et al. Murine CD27(-) Vgamma6(+) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci USA 2014; 111: E3562–E3570.



This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.